Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Waldthaler C, Stauder R, Schnallinger M, Schreieck S, Hager J, Oexle H, Zangerl G, Verdorfer I, Zabernigg A, Gastl G, Fiegl M. Waldthaler C, et al. Among authors: zabernigg a. Wien Klin Wochenschr. 2011 May;123(9-10):269-75. doi: 10.1007/s00508-011-1558-7. Epub 2011 Apr 13. Wien Klin Wochenschr. 2011. PMID: 21479652
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M. Kocher F, et al. Among authors: zabernigg a. Lung Cancer. 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25564398
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Fiegl M, et al. Among authors: zabernigg a. Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30. Ann Hematol. 2014. PMID: 24292560 Clinical Trial.
Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
Hilbe W, Pall G, Kocher F, Pircher A, Zabernigg A, Schmid T, Schumacher M, Jamnig H, Fiegl M, Gächter A, Freund M, Kendler D, Manzl C, Zelger B, Popper H, Wöll E. Hilbe W, et al. Among authors: zabernigg a. PLoS One. 2015 May 28;10(5):e0125364. doi: 10.1371/journal.pone.0125364. eCollection 2015. PLoS One. 2015. PMID: 26020783 Free PMC article. Clinical Trial.
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle A, Melchardt T, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Voskova D, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Weiss L, Magnes T, Pleyer L, Klingler A, Mayer J, Greil R. Egle A, et al. Among authors: zabernigg a. Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19. Cancer Med. 2019. PMID: 30888118 Free PMC article. Clinical Trial.
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, Mühlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Fiegl M, et al. Among authors: zabernigg a. Ann Oncol. 2010 Dec;21(12):2410-2419. doi: 10.1093/annonc/mdq236. Epub 2010 May 13. Ann Oncol. 2010. PMID: 20466745 Free article.
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Fiegl M, et al. Among authors: zabernigg a. Cancer. 2006 Nov 15;107(10):2408-16. doi: 10.1002/cncr.22263. Cancer. 2006. PMID: 17054106 Free article.
68 results